Barclays
AGL icon

Barclays’s Agilon Health AGL Stock Holding History

Barclays’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.96M Buy
49,696
+42,132
+557% +$4.1M ﹤0.01% 2170
2026
Q2 		$811K Buy
7,564
+2,101
+38% +$138K ﹤0.01% 2923
2026
Q1 		$43.2K Sell
5,463
-15,682
-74% -$254K ﹤0.01% 4374
2025
Q4 		$364K Buy
21,145
+1,500
+8% +$29.1K ﹤0.01% 4032
2025
Q3 		$506K Sell
19,645
-7,162
-27% -$271K ﹤0.01% 3806
2025
Q2 		$1.54M Buy
26,807
+7,985
+42% +$640K ﹤0.01% 3046
2025
Q1 		$2.04M Sell
18,822
-5,292
-22% -$461K ﹤0.01% 2617
2024
Q4 		$1.15M Sell
24,114
-25,044
-51% -$1.51M ﹤0.01% 3289
2024
Q3 		$4.83M Buy
49,158
+8,593
+21% +$1.11M ﹤0.01% 2122
2024
Q2 		$6.63M Buy
40,565
+21,870
+117% +$3.12M ﹤0.01% 1382
2024
Q1 		$2.85M Buy
18,695
+6,390
+52% +$1.06M ﹤0.01% 2275
2023
Q4 		$3.86M Sell
12,305
-606
-5% -$219K ﹤0.01% 2349
2023
Q3 		$5.73M Sell
12,911
-5,045
-28% -$2.28M ﹤0.01% 1250
2023
Q2 		$7.78M Buy
17,956
+17,427
+3,294% +$9.8M ﹤0.01% 1096
2023
Q1 		$314K Sell
529
-475
-47% -$266K ﹤0.01% 3555
2022
Q4 		$405K Sell
1,004
-2,594
-72% -$1.22M ﹤0.01% 3441
2022
Q3 		$2.11M Buy
3,598
+1,599
+80% +$957K ﹤0.01% 1711
2022
Q2 		$1.09M Buy
1,999
+1,593
+392% +$806K ﹤0.01% 2276
2022
Q1 		$258K Buy
+406
New +$209K ﹤0.01% 3271

Other funds holding AGL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays's AGL Position: Q3 2026 in Review

Barclays increased its Agilon Health (AGL) stake by 557% in Q3 2026, buying an estimated $4.1M and bringing the position to 49,696 shares worth $3.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

Barclays first reported a position in AGL in Q1 2022 and has held it in 19 quarters since. The position peaked at $7.78M in Q2 2023. 81 funds tracked by Wall St. Rank hold AGL as of Q3 2026.

  • Barclays held 49,696 shares of Agilon Health worth $3.96M as of Q3 2026.
  • Barclays bought 42,132 Agilon Health shares in Q3 2026, an estimated $4.1M.
  • Agilon Health made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2170 holding.
  • Barclays first reported a position in Agilon Health in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Agilon Health position peaked at $7.78M in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Agilon Health as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.